Second breakthrough therapy mark for Novartis’s Kisqali

Second breakthrough therapy mark for Novartis’s Kisqali

January 3, 2018 Off By Dino Mustafić

Novartis on Wednesday sadi that Kisqali has gotten US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor.

This Breakthrough Therapy designation is based on positive results of the Phase III MONALEESA-7 trial demonstrating Kisqali in combination with tamoxifen or an aromatase inhibitor as initial endocrine-based therapy significantly prolonged progression-free survival (PFS) compared to endocrine therapy alone.

“This Breakthrough Therapy designation reflects the significance and promise of the MONALEESA-7 data presented at SABCS last month,” said Samit Hirawat, Head, Novartis Oncology Global Drug Development. “Younger women often have distinct treatment goals and needs, and it is important for oncologists to offer effective and well-studied treatment options for their specific disease. We look forward to working with FDA to make this combination therapy available to premenopausal women living with HR+/HER2- advanced breast cancer in the US as soon as possible.”

This Breakthrough Therapy designation marks the second for Kisqali. The first Breakthrough Therapy designation for Kisqali was granted in August 2016 based on results of the Phase III MONALEESA-2 trial.

Image: A sign marks a building on Novartis’ campus in Cambridge, Massachusetts, U.S., February 28, 2017. Picture taken February 28, 2017. REUTERS/Brian Snyder